ArticleEuropean journal of case reports in internal medicine2025
Rhabdomyolysis as an Uncommon Manifestation of Anoctamin-5 Muscular Dystrophy.
Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anoctamin-5 (ANO5) muscular dystrophy is a rare neuromuscular disease. Muscular weakness and impaired gait may be evident at the moment of diagnosis, serving as defining characteristics of additional muscular dystrophies. Rhabdomyolysis, on the other hand, is a rare presentation Understanding this phenotype is of great importance since it can go unnoticed by physicians, leading to misdiagnosis of metabolic myopathies or delayed diagnosis. We discuss a case of recurrent rhabdomyolysis due to ANO5 muscular dystrophy. Case Report: A 34-year-old man was referred to our Reference Centre for Hereditary and Metabolic Diseases due to incidentally elevated creatine kinase levels of 4369 U/l (normal value: < 171 U/l) in the context of acute renal colic. He described a 10-year history of progressive myalgia induced by physical activity, particularly in the lower extremities, muscle spasms, and sporadic reddish to brown urine. Although no muscle weakness was detected upon neurological examination, bilateral calf hypertrophy was noted. A comprehensive laboratory analysis was conducted to exclude acquired causes of rhabdomyolysis, including electrolyte abnormalities, endocrine disruptions, and autoimmune myopathies. Considering the high suspicion of an inherited aetiology, we proceeded with next-generation sequencing of rhabdomyolysis-related genes. Genetic testing revealed a c.1180+6t>Cp homozygous mutation in ANO5 gene, which confirmed anoctamin-5 muscular dystrophy. Conclusions: ANO5 muscular dystrophy is a rare cause of inherited rhabdomyolysis. Understanding this phenotype is crucial for accurate and timely diagnosis. Currently, there is no specific treatment for this condition, but management should include avoiding heavy muscle training and use of statins. LEARNING POINTS: Anoctamin-5 (ANO5) muscular dystrophy is a rare neuromuscular disease originated by homozygous mutations in ANO5, a gene encoding a protein with the same name located on chromosome 11. ANO5 is a calcium-activated chloride channel that is highly expressed in heart and skeletal muscle. It is a rare cause of inherited rhabdomyolysis. Understanding this phenotype is crucial for accurate and timely diagnosis.We must emphasize how meticulous medical history taking along with a high index of suspicion are essential to diagnose this disease.Currently, there is no specific treatment for this condition, but management should include avoiding heavy muscle training and use of statins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.